Urovant Sciences (UROV) Misses Q4 EPS by 44c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Urovant Sciences (UROV) Misses Q4 EPS by 44c

Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results

June 18, 2020 4:05 PM EDT

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020.

The fiscal fourth quarter of 2019 marked achievement of key milestones for Urovant Sciences, including publication of results from the international EMPOWUR Phase 3 pivotal trial and acceptance of the Companys new drug application (NDA) for vibegron for the treatment of overactive bladder (OAB) by the U.S. Food and Drug Administration (FDA).

The 2019 fiscal year and fourth quarter have been transformational for our company, said James Robinson, president and... More